Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MPI | P34949 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | XPO1 | O14980 | 2/20 | 0.34 |
| ▸ | ERN1 | O75460 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | CCR4 | P51679 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25962882 | 0.81 | AURKA (0.39) | ALDH1A1KDM4EERN1GAATSHR | |
| SCHEMBL29581116 | 0.81 | ERN1 (0.39) | ALDH1A1KDM4EERN1TSHRTDP1 | |
| SCHEMBL20719582 | 0.80 | ALDH1A1 (0.42) | ALDH1A1KDM4EMEN1MAPTMPI | |
| SCHEMBL30448383 | 0.80 | ALDH1A1 (0.42) | ALDH1A1KDM4EMEN1MAPTMPI | |
| SCHEMBL6953346 | 0.78 | KMT2A (0.38) | ALDH1A1MEN1MAPTKMT2AXPO1 | |
| SCHEMBL20539389 | 0.78 | TDP1 (0.41) | ALDH1A1KDM4EMEN1MAPTMPI | |
| SCHEMBL29580781 | 0.78 | TDP1 (0.41) | ALDH1A1KDM4EMEN1MAPTMPI | |
| SCHEMBL29580580 | 0.76 | ERN1 (0.38) | ALDH1A1KDM4EMEN1MAPTMPI | |
| SCHEMBL23961392 | 0.73 | ERN1 (0.40) | ALDH1A1KDM4EMEN1MAPTMPI | |
| SCHEMBL29580627 | 0.72 | KDM4E (0.39) | ALDH1A1KDM4EMAPTXPO1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590062-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| CN-118878461-A | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2024-11-01 | — | — | CN | disclosed |
| CN-114591226-B | Preparation method of nicotinaldehyde derivative | 南京益恩生物科技有限公司 | 2024-09-17 | — | — | CN | disclosed |
| US-20240246964-A1 | SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-25 | — | — | US | disclosed |
| EP-4313968-A2 | SUBSTITUTED 1-ARYL-1'-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1'-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022208269-A2 | SUBSTITUTED 1-ARYL-1'-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1'-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2022-10-06 | — | — | WO | disclosed |
| EP-4026835-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-4026835-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| CN-114591226-A | Preparation method of nicotinaldehyde derivative | 南京益恩生物科技有限公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-114437051-A | Biphenyl compound, preparation method and application thereof | 药康众拓(江苏)医药科技有限公司 | 2022-05-06 | — | — | CN | disclosed |
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-10-21 | — | — | US | disclosed |
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-10-21 | — | — | US | disclosed |
| EP-3612525-A1 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2020-02-26 | — | — | EP | disclosed |
| WO-2018195321-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2018-10-25 | — | — | WO | disclosed |
| US-20180305315-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2018-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | CD274, PDCD1, PDCD1LG2 | ALDH1A1 104/4885KDM4E 1276/4885MEN1 1022/4885 |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | CD274, PDCD1LG2, PDCD1 | ALDH1A1 409/4885KDM4E 1970/4885MEN1 3035/4885 |
| US-20240246964-A1 | SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | HAVCR2, HDGF, HCCS | ALDH1A1 382/4885KDM4E 840/4885MEN1 1254/4885 |
| US-20180305315-A1 | PD-1/PD-L1 INHIBITORS | CD274, PDCD1, PDCD1LG2 | ALDH1A1 104/4885KDM4E 1276/4885MEN1 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.